

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/064043 A1

(51) International Patent Classification:

C07K 16/22 (2006.01) C07K 16/46 (2006.01)

C07K 16/24 (2006.01) A61P 29/00 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/076524

(22) International Filing Date:

27 September 2021 (27.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/084,358 28 September 2020 (28.09.2020) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **WELSH, Fraser**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **CHESELL, Tharani**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **TAN, Keith**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **OSTENFELD, Thor**; MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **JENKINS, Richard**; AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with information concerning incorporation by reference of missing element or part (Rule 20.6)



WO 2022/064043 A1

(54) Title: COMPOUNDS AND METHODS FOR TREATING PAIN

(57) Abstract: The disclosure provides novel methods and dosage regimens for use in treating or preventing pain, wherein the binding molecule comprises an NGF antagonist domain and a TNF α antagonist domain, wherein the NGF antagonist domain is an anti-NGF antibody or an antigen-binding fragment thereof and wherein the TNF α antagonist domain comprises a soluble TNF α binding fragment of TNFR.